EGFR and neoplasm: While the primary anti-tumor activity of EGFR mAbs is attributed to blocking receptor activation, other mechanisms likely contribute to the anti-tumor effects such as receptor downregulation56 and antibody-dependent cellular cytotoxicity (ADCC).57